Community-acquired pneumonia primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 2: | Line 2: | ||
{{Community-acquired pneumonia}} | {{Community-acquired pneumonia}} | ||
==Vaccines== | ==Vaccines== | ||
===Pneumococcal Polysaccharide Vaccine=== | |||
{| style="border: 2px solid #696969;" align="center" | {| style="border: 2px solid #696969;" align="center" | ||
|+ <SMALL>'' Vaccine prevention of community-acquired pneumonia.''<ref name="Harper-2005">{{Cite journal | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi = | PMID = 16086456 }}</ref></SMALL> | |+ <SMALL>'' Vaccine prevention of community-acquired pneumonia.''<ref name="Harper-2005">{{Cite journal | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi = | PMID = 16086456 }}</ref></SMALL> | ||
Revision as of 21:13, 29 January 2014
|
Community-Acquired Pneumonia Microchapters |
|
Differentiating Community-acquired pneumonia from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Community-acquired pneumonia primary prevention On the Web |
|
American Roentgen Ray Society Images of Community-acquired pneumonia primary prevention |
|
Directions to Hospitals Treating Community-acquired pneumonia |
|
Risk calculators and risk factors for Community-acquired pneumonia primary prevention |
Vaccines
Pneumococcal Polysaccharide Vaccine
| Factor | Pneumococcal polysaccharide vaccine |
| ▸ Route of administration | ▸ Intramuscular injection |
| ▸ Type of vaccine | ▸Bacterial component (polysaccharide capsule) |
| ▸ Recommended groups | ▸All persons ≥ 65 years of age 'High-risk persons 2–64 years of age' 'Current smokers' |
| ▸ Specific high-risk indications for vaccination | ▸ Chronic cardiovascular, pulmonary, renal, or liver disease ▸Diabetes mellitus ▸Cerebrospinal fluid leaks ▸ Alcoholism ▸ Asplenia ▸ Immunocompromising conditions / medications ▸Native Americans and Alaska natives ▸Long-term care facility residents |
| ▸ Revaccination schedule | ▸ One-time revaccination after 5 years for ▸ (1) adults 65 years of age, if the first dose is received before age 65 years ▸ (2) persons with asplenia ▸ (3) immunocompromised persons |
Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.[1]